TY  - JOUR
AU  - Alonso, Cristina
AU  - Satta, Valentina
AU  - Hernández Fisac, Inés
AU  - Fernández Ruiz, José Javier
AU  - Sagredo Ezquioga, Onintza
PY  - 2023
DO  - 10.1016/j.neuropharm.2023.109602
UR  - https://hdl.handle.net/20.500.14352/103445
T2  - Neuropharmacology
AB  - Cannabidiol (CBD) has been recently approved as an antiseizure agent in Dravet Syndrome (DS), a pediatric epileptic encephalopathy, but CBD could also be active against associated comorbidities. Such associated comorbidities were also attenuated by...
LA  - eng
PB  - Elsevier
KW  - Dravet syndrome
KW  - Cannabinoids
KW  - β-caryophyllene
KW  - Cannabidiol
KW  - Syn1-Cre/Scn1aWT/A1783V mice
KW  - LPS-stimulated BV2 cells
TI  - Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
TY  - journal article
VL  - 237
ER  -